LEXICON PHARMACEUTICALS INC (LXRX)

US5288723027 - Common Stock

0.7147  -0.01 (-1.23%)

After market: 0.642 -0.07 (-10.17%)

Fundamental Rating

2

Taking everything into account, LXRX scores 2 out of 10 in our fundamental rating. LXRX was compared to 565 industry peers in the Biotechnology industry. LXRX may be in some trouble as it scores bad on both profitability and health. LXRX is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

LXRX had negative earnings in the past year.
LXRX had a negative operating cash flow in the past year.
LXRX had negative earnings in 4 of the past 5 years.
In the past 5 years LXRX reported 4 times negative operating cash flow.

1.2 Ratios

LXRX has a worse Return On Assets (-67.39%) than 64.07% of its industry peers.
LXRX's Return On Equity of -121.22% is in line compared to the rest of the industry. LXRX outperforms 40.88% of its industry peers.
Industry RankSector Rank
ROA -67.39%
ROE -121.22%
ROIC N/A
ROA(3y)-64.59%
ROA(5y)-38.28%
ROE(3y)-118.18%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of LXRX (93.54%) is better than 94.87% of its industry peers.
LXRX's Gross Margin has been stable in the last couple of years.
LXRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.65%

More info and screens

3

2. Health

2.1 Basic Checks

LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
LXRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LXRX has more shares outstanding
The debt/assets ratio for LXRX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -8.63, we must say that LXRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.63, LXRX is not doing good in the industry: 70.62% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.56 indicates that LXRX is somewhat dependend on debt financing.
The Debt to Equity ratio of LXRX (0.56) is worse than 75.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z -8.63
ROIC/WACCN/A
WACC12.94%

2.3 Liquidity

LXRX has a Current Ratio of 7.45. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX has a better Current ratio (7.45) than 70.62% of its industry peers.
LXRX has a Quick Ratio of 7.43. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX has a better Quick ratio (7.43) than 70.62% of its industry peers.
Industry RankSector Rank
Current Ratio 7.45
Quick Ratio 7.43

More info and screens

5

3. Growth

3.1 Past

LXRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.32%.
Looking at the last year, LXRX shows a very strong growth in Revenue. The Revenue has grown by 945.80%.
LXRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -54.71% yearly.
EPS 1Y (TTM)1.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)945.8%
Revenue growth 3Y-63.12%
Revenue growth 5Y-54.71%
Sales Q2Q%980.25%

3.2 Future

The Earnings Per Share is expected to grow by 16.58% on average over the next years. This is quite good.
Based on estimates for the next years, LXRX will show a very strong growth in Revenue. The Revenue will grow by 155.21% on average per year.
EPS Next Y12.15%
EPS Next 2Y18.74%
EPS Next 3Y13.62%
EPS Next 5Y16.58%
Revenue Next Year538.53%
Revenue Next 2Y176.53%
Revenue Next 3Y149.03%
Revenue Next 5Y155.21%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LXRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LXRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

LXRX's earnings are expected to grow with 13.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.74%
EPS Next 3Y13.62%

More info and screens

0

5. Dividend

5.1 Amount

LXRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (12/20/2024, 8:23:15 PM)

After market: 0.642 -0.07 (-10.17%)

0.7147

-0.01 (-1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners77.67%
Inst Owner Change3.38%
Ins Owners0.77%
Ins Owner Change0%
Market Cap258.36M
Analysts81.67
Price Target3.67 (413.5%)
Short Float %9.11%
Short Ratio7.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.19%
Min EPS beat(2)-7.28%
Max EPS beat(2)11.66%
EPS beat(4)3
Avg EPS beat(4)3.71%
Min EPS beat(4)-7.28%
Max EPS beat(4)11.66%
EPS beat(8)5
Avg EPS beat(8)-1.81%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)13
Avg EPS beat(16)8.24%
Revenue beat(2)0
Avg Revenue beat(2)-42.19%
Min Revenue beat(2)-42.95%
Max Revenue beat(2)-41.43%
Revenue beat(4)0
Avg Revenue beat(4)-37.48%
Min Revenue beat(4)-44.59%
Max Revenue beat(4)-20.92%
Revenue beat(8)1
Avg Revenue beat(8)-0.68%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-29.13%
PT rev (3m)-41.94%
EPS NQ rev (1m)3.87%
EPS NQ rev (3m)35.98%
EPS NY rev (1m)-0.24%
EPS NY rev (3m)-0.49%
Revenue NQ rev (1m)-1.41%
Revenue NQ rev (3m)-43.32%
Revenue NY rev (1m)-28.15%
Revenue NY rev (3m)-32.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 49.41
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB 1.93
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.01
BVpS0.49
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.39%
ROE -121.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.54%
FCFM N/A
ROA(3y)-64.59%
ROA(5y)-38.28%
ROE(3y)-118.18%
ROE(5y)-56.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.61%
Cap/Sales 10.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.45
Quick Ratio 7.43
Altman-Z -8.63
F-Score5
WACC12.94%
ROIC/WACCN/A
Cap/Depr(3y)269.95%
Cap/Depr(5y)163.2%
Cap/Sales(3y)579.68%
Cap/Sales(5y)347.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y12.15%
EPS Next 2Y18.74%
EPS Next 3Y13.62%
EPS Next 5Y16.58%
Revenue 1Y (TTM)945.8%
Revenue growth 3Y-63.12%
Revenue growth 5Y-54.71%
Sales Q2Q%980.25%
Revenue Next Year538.53%
Revenue Next 2Y176.53%
Revenue Next 3Y149.03%
Revenue Next 5Y155.21%
EBIT growth 1Y-36.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.32%
EBIT Next 3Y-0.95%
EBIT Next 5YN/A
FCF growth 1Y-131.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-130.73%
OCF growth 3YN/A
OCF growth 5YN/A